IDEAS home Printed from https://ideas.repec.org/r/sae/medema/v20y2000i3p332-342.html
   My bibliography  Save this item

Willingness to Pay for a Quality-adjusted Life Year

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Dorothea Kesztyüs & Romy Lauer & Anja Schreiber & Tibor Kesztyüs & Reinhold Kilian & Jürgen Steinacker, 2014. "Parents’ willingness to pay for the prevention of childhood overweight and obesity," Health Economics Review, Springer, vol. 4(1), pages 1-8, December.
  2. Pinto-Prades, Jose Luis & Loomes, Graham & Brey, Raul, 2009. "Trying to estimate a monetary value for the QALY," Journal of Health Economics, Elsevier, vol. 28(3), pages 553-562, May.
  3. Amaia Malet-Larrea & Estíbaliz Goyenechea & Miguel A. Gastelurrutia & Begoña Calvo & Victoria García-Cárdenas & Juan M. Cabases & Aránzazu Noain & Fernando Martínez-Martínez & Daniel Sabater-Hernández, 2017. "Cost analysis and cost-benefit analysis of a medication review with follow-up service in aged polypharmacy patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(9), pages 1069-1078, December.
  4. Cam Donaldson & Helen Mason & Phil Shackley, 2012. "Contingent Valuation in Health Care," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 40, Edward Elgar Publishing.
  5. Matthew Calver, 2016. "Measuring the Appropriate Outcomes for Better Decision-Making: A Framework to Guide the Analysis of Health Policy," CSLS Research Reports 2016-03, Centre for the Study of Living Standards.
  6. Amirabbas Mofidi & Emile Tompa & Christina Kalcevich & Christopher McLeod & Martin Lebeau & Chaojie Song & Joanne Kim & Paul A. Demers, 2022. "Occupational Exposure to Wood Dust and the Burden of Nasopharynx and Sinonasal Cancer in Canada," IJERPH, MDPI, vol. 19(3), pages 1-16, January.
  7. Jun Li & Benjamin H K Yip & Chichiu Leung & Wankyo Chung & Kin On Kwok & Emily Y Y Chan & Engkiong Yeoh & Puihong Chung, 2018. "Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-18, January.
  8. John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
  9. Clément Carbonnier, 2023. "Welfare Economics and Neoliberalism: Interpreting the ideal type of perfect competition general equilibrium," Working Papers hal-04062786, HAL.
  10. Stein, Alexander J., 2013. "Rethinking the measurement of undernutrition in a broader health context: Should we look at possible causes or actual effects," IFPRI discussion papers 1298, International Food Policy Research Institute (IFPRI).
  11. Katherine Stackelberg & James Hammitt, 2009. "Use of Contingent Valuation to Elicit Willingness-to-Pay for the Benefits of Developmental Health Risk Reductions," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 43(1), pages 45-61, May.
  12. Michael Jones-Lee & Susan Chilton & Hugh Metcalf & Jytte Nielsen, 2015. "Valuing gains in life expectancy: Clarifying some ambiguities," Journal of Risk and Uncertainty, Springer, vol. 51(1), pages 1-21, August.
  13. James Hammitt, 2013. "Admissible utility functions for health, longevity, and wealth: integrating monetary and life-year measures," Journal of Risk and Uncertainty, Springer, vol. 47(3), pages 311-325, December.
  14. Howard, David H., 2005. "Life expectancy and the value of early detection," Journal of Health Economics, Elsevier, vol. 24(5), pages 891-906, September.
  15. Zarko Kalamov, 2021. "Evaluating Marginal Internalities: A New Approach," CESifo Working Paper Series 9476, CESifo.
  16. Scott Johnson & Matthew Davis & Anna Kaltenboeck & Howard Birnbaum & ElizaBeth Grubb & Marcy Tarrants & Andrew Siderowf, 2011. "Early retirement and income loss in patients with early and advanced Parkinson’s disease," Applied Health Economics and Health Policy, Springer, vol. 9(6), pages 367-376, November.
  17. Frank Lichtenberg, 2015. "The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011," International Journal of Health Economics and Management, Springer, vol. 15(3), pages 339-359, September.
  18. Brian Mills & Dan Unrau & Laurel Pentelow & Kelsey Spring, 2010. "Assessment of lightning-related damage and disruption in Canada," Natural Hazards: Journal of the International Society for the Prevention and Mitigation of Natural Hazards, Springer;International Society for the Prevention and Mitigation of Natural Hazards, vol. 52(2), pages 481-499, February.
  19. Khachapon Nimdet & Nathorn Chaiyakunapruk & Kittaya Vichansavakul & Surachat Ngorsuraches, 2015. "A Systematic Review of Studies Eliciting Willingness-to-Pay per Quality-Adjusted Life Year: Does It Justify CE Threshold?," PLOS ONE, Public Library of Science, vol. 10(4), pages 1-16, April.
  20. S. Olofsson & U.-G. Gerdtham & L. Hultkrantz & U. Persson, 2019. "Value of a QALY and VSI estimated with the chained approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(7), pages 1063-1077, September.
  21. Hoy, Michael & Polborn, Mattias K., 2015. "The value of technology improvements in games with externalities: A fresh look at offsetting behavior," Journal of Public Economics, Elsevier, vol. 131(C), pages 12-20.
  22. Gandjour, Afschin & Chernyak, Nadja, 2011. "A new prize system for drug innovation," Health Policy, Elsevier, vol. 102(2), pages 170-177.
  23. Mulligan, Karen & Baid, Drishti & Doctor, Jason N. & Phelps, Charles E. & Lakdawalla, Darius N., 2024. "Risk preferences over health: Empirical estimates and implications for medical decision-making," Journal of Health Economics, Elsevier, vol. 94(C).
  24. Lakdawalla, Darius N. & Phelps, Charles E., 2020. "Health technology assessment with risk aversion in health," Journal of Health Economics, Elsevier, vol. 72(C).
  25. Richard H. Chapman & Marc Berger & Milton C. Weinstein & Jane C. Weeks & Sue Goldie & Peter J. Neumann, 2004. "When does quality‐adjusting life‐years matter in cost‐effectiveness analysis?," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 429-436, May.
  26. Hui Zhang & Christian Wernz & Danny R. Hughes, 2018. "Modeling and designing health care payment innovations for medical imaging," Health Care Management Science, Springer, vol. 21(1), pages 37-51, March.
  27. Tatia Woodward & Eskinder Tafesse & Peter Quon & Arthur Lazarus, 2010. "Cost Effectiveness of Adjunctive Quetiapine Fumarate Extended-Release Tablets with Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder," PharmacoEconomics, Springer, vol. 28(9), pages 751-764, September.
  28. Sood Neeraj & Philipson Tomas J. & Huckfeldt Peter, 2013. "Quantifying the Value of Personalized Medicines: Evidence from COX-2 Inhibitors," Forum for Health Economics & Policy, De Gruyter, vol. 16(1), pages 101-122, April.
  29. Kevin Haninger & James K. Hammitt, 2011. "Diminishing Willingness to Pay per Quality‐Adjusted Life Year: Valuing Acute Foodborne Illness," Risk Analysis, John Wiley & Sons, vol. 31(9), pages 1363-1380, September.
  30. Stephanie Earnshaw & Jonathan Graham & MerriKay Oleen-Burkey & Jane Castelli-Haley & Kenneth Johnson, 2009. "Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis," Applied Health Economics and Health Policy, Springer, vol. 7(2), pages 91-108, June.
  31. Benjamin B. Lockwood & Dmitry Taubinsky, 2017. "Regressive Sin Taxes," NBER Working Papers 23085, National Bureau of Economic Research, Inc.
  32. James K. Hammitt, 2023. "Consistent valuation of a reduction in mortality risk using values per life, life year, and quality‐adjusted life year," Health Economics, John Wiley & Sons, Ltd., vol. 32(9), pages 1964-1981, September.
  33. Hammitt, James K. & Tuncel, Tuba, 2023. "Monetary values of increasing life expectancy: sensitivity to shifts of the survival curve," TSE Working Papers 23-1416, Toulouse School of Economics (TSE).
  34. Donald S Shepard & Yara A Halasa & Dina M Fonseca & Ary Farajollahi & Sean P Healy & Randy Gaugler & Kristen Bartlett-Healy & Daniel A Strickman & Gary G Clark, 2014. "Economic Evaluation of an Area-Wide Integrated Pest Management Program to Control the Asian Tiger Mosquito in New Jersey," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-11, October.
  35. Robinson Lisa A. & Hammitt James K., 2013. "Skills of the trade: valuing health risk reductions in benefit-cost analysis," Journal of Benefit-Cost Analysis, De Gruyter, vol. 4(1), pages 107-130, March.
  36. Tilling, C & Krol, M & Tsuchiya, A & Brazier, J & van Exel, J & Brouwer, W, 2009. "Measuring the value of life: exploring a new method for deriving the monetary value of a QALY," MPRA Paper 29911, University Library of Munich, Germany.
  37. Coskeran, Thomas & Denman, Antony & Phillips, Paul & Tornberg, Roger, 2007. "The cost-effectiveness of radon-proof membranes in new homes: A case study from Brixworth, Northamptonshire, UK," Health Policy, Elsevier, vol. 81(2-3), pages 195-206, May.
  38. Helen Mason & Michael Jones‐Lee & Cam Donaldson, 2009. "Modelling the monetary value of a QALY: a new approach based on UK data," Health Economics, John Wiley & Sons, Ltd., vol. 18(8), pages 933-950, August.
  39. Jonathan Skinner & Douglas Staiger, 2015. "Technology Diffusion and Productivity Growth in Health Care," The Review of Economics and Statistics, MIT Press, vol. 97(5), pages 951-964, December.
  40. Svensson, Mikael & Hultkrantz, Lars, 2012. "The Willingness to Pay for a QALY - Results based on value of statistical life estimates in Sweden," Karlstad University Working Papers in Economics 2, Karlstad University, Department of Economics.
  41. Hammitt, James K., 2023. "Consistent Valuation of a Reduction in Mortality Risk using Values per Life, Life Year, and Quality-Adjusted Life Year," TSE Working Papers 23-1431, Toulouse School of Economics (TSE).
  42. Tomas J. Philipson & Gary Becker & Dana Goldman & Kevin M. Murphy, 2010. "Terminal Care and The Value of Life Near Its End," NBER Working Papers 15649, National Bureau of Economic Research, Inc.
  43. James K. Hammitt & Tuba Tunçel, 2023. "Monetary values of increasing life expectancy: Sensitivity to shifts of the survival curve," Journal of Risk and Uncertainty, Springer, vol. 67(3), pages 239-269, December.
  44. Samuel Shillcutt & Damian Walker & Catherine Goodman & Anne Mills, 2009. "Cost Effectiveness in Low- and Middle-Income Countries," PharmacoEconomics, Springer, vol. 27(11), pages 903-917, November.
  45. Ivar Kristiansen & Kerstin Bingefors & Dag Nyholm & Dag Isacson, 2009. "Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden," Applied Health Economics and Health Policy, Springer, vol. 7(3), pages 167-180, September.
  46. Frank R. Lichtenberg, 2017. "The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013," Latin American Economic Review, Springer;Centro de Investigaciòn y Docencia Económica (CIDE), vol. 26(1), pages 1-22, December.
  47. Son Nghiem & Nicholas Graves & Adrian Barnett & Catherine Haden, 2017. "Cost-effectiveness of national health insurance programs in high-income countries: A systematic review," PLOS ONE, Public Library of Science, vol. 12(12), pages 1-11, December.
  48. Zethraeus, Niklas & Borgström, Fredrik & Jönsson, Bengt & Kanis, John, 2004. "A reassessment of the cost-effectiveness of hormone replacement therapy in Sweden – results based on the Women’s Health Initiative randomised controlled trial," SSE/EFI Working Paper Series in Economics and Finance 571, Stockholm School of Economics.
  49. Ted R Miller & Geetha M Waehrer & Debora L Oh & Sukhdip Purewal Boparai & Sheila Ohlsson Walker & Sara Silverio Marques & Nadine Burke Harris, 2020. "Adult health burden and costs in California during 2013 associated with prior adverse childhood experiences," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-15, January.
  50. Takeru Shiroiwa & Yoon‐Kyoung Sung & Takashi Fukuda & Hui‐Chu Lang & Sang‐Cheol Bae & Kiichiro Tsutani, 2010. "International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?," Health Economics, John Wiley & Sons, Ltd., vol. 19(4), pages 422-437, April.
  51. Franz Hessel & Christoph Wegner & Johannes Müller & Christina Glaveris & Jürgen Wasem, 2004. "Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(1), pages 58-63, February.
  52. Herrera-Araujo, Daniel & Hammitt, James K. & Rheinberger, Christoph M., 2020. "Theoretical bounds on the value of improved health," Journal of Health Economics, Elsevier, vol. 72(C).
  53. Hunt Allcott & Benjamin B Lockwood & Dmitry Taubinsky, 2019. "Regressive Sin Taxes, with an Application to the Optimal Soda Tax," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 134(3), pages 1557-1626.
  54. James K. Hammitt, 2017. "Valuing Non-Fatal Health Risks: Monetary and Health-Utility Measures," Revue économique, Presses de Sciences-Po, vol. 68(3), pages 335-356.
  55. James P Moriarty & Bijan J Borah & Robert L Foote & Jose S Pulido & Nilay D Shah, 2015. "Cost-Effectiveness of Proton Beam Therapy for Intraocular Melanoma," PLOS ONE, Public Library of Science, vol. 10(5), pages 1-14, May.
  56. Li, Y. & Zhu, M. & Klein, R. & Kong, N., 2014. "Using a partially observable Markov chain model to assess colonoscopy screening strategies – A cohort study," European Journal of Operational Research, Elsevier, vol. 238(1), pages 313-326.
  57. Don Kenkel, 2006. "WTP- and QALY-Based Approaches to Valuing Health for Policy: Common Ground and Disputed Territory," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 34(3), pages 419-437, July.
  58. Benjamin Ho & Sita N. Slavov, 2012. "An alternative perspective on health inequality," Economics Bulletin, AccessEcon, vol. 32(4), pages 3182-3196.
  59. Jacopo Garlasco & Mario Cesare Nurchis & Valerio Bordino & Martina Sapienza & Gerardo Altamura & Gianfranco Damiani & Maria Michela Gianino, 2022. "Cancers: What Are the Costs in Relation to Disability-Adjusted Life Years? A Systematic Review and Meta-Analysis," IJERPH, MDPI, vol. 19(8), pages 1-17, April.
  60. Ryen, Linda & Svensson, Mikael, 2014. "The Willingness to Pay for a QALY: a Review of the Empirical Literature," Karlstad University Working Papers in Economics 12, Karlstad University, Department of Economics.
  61. Marilyn S. Nanney & Samuel L. Myers & Man Xu & Kateryna Kent & Thomas Durfee & Michele L. Allen, 2019. "The Economic Benefits of Reducing Racial Disparities in Health: The Case of Minnesota," IJERPH, MDPI, vol. 16(5), pages 1-13, March.
  62. Reza Yaesoubi & Stephen Roberts, 2010. "A game-theoretic framework for estimating a health purchaser’s willingness-to-pay for health and for expansion," Health Care Management Science, Springer, vol. 13(4), pages 358-377, December.
  63. Dorte Gyrd‐Hansen, 2003. "Willingness to pay for a QALY," Health Economics, John Wiley & Sons, Ltd., vol. 12(12), pages 1049-1060, December.
  64. Tomas J. Philipson & Gary Becker & Dana Goldman & Kevin M. Murphy, 2010. "Terminal Care and The Value of Life Near Its End," NBER Working Papers 15649, National Bureau of Economic Research, Inc.
  65. Smith, Richard D. & Richardson, Jeff, 2005. "Can we estimate the `social' value of a QALY?: Four core issues to resolve," Health Policy, Elsevier, vol. 74(1), pages 77-84, September.
  66. Shafrin, Jason & Skornicki, Michelle & Brauer, Michelle & Villeneuve, Julie & Lees, Michael & Hertel, Nadine & Penrod, John R. & Jansen, Jeroen, 2018. "An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?," Health Policy, Elsevier, vol. 122(6), pages 607-613.
  67. Michael Kattan & Stephanie Earnshaw & Cheryl McDade & Libby Black & Gerald Andriole, 2011. "Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE Clinical trial," Applied Health Economics and Health Policy, Springer, vol. 9(5), pages 305-315, September.
  68. Daniel Bauer & Darius Lakdawalla & Julian Reif, 2018. "Mortality Risk, Insurance, and the Value of Life," NBER Working Papers 25055, National Bureau of Economic Research, Inc.
  69. Patti Curl & Igor Vujic & Laura J van ‘t Veer & Susana Ortiz-Urda & James G Kahn, 2014. "Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma," PLOS ONE, Public Library of Science, vol. 9(9), pages 1-9, September.
  70. Christian R. C. Kouakou & Thomas G. Poder, 2022. "Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 277-299, March.
  71. Lichtenberg Frank R., 2017. "The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004–2012," Forum for Health Economics & Policy, De Gruyter, vol. 20(1), pages 1-28, June.
  72. Kittiphong Thiboonboon & Wantanee Kulpeng & Yot Teerawattananon, 2018. "An economic analysis of chromosome testing in couples with children who have structural chromosome abnormalities," PLOS ONE, Public Library of Science, vol. 13(6), pages 1-14, June.
  73. Daniel Grima & Lisa Bernard & Elizabeth Dunn & Philip McFarlane & David Mendelssohn, 2012. "Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis," PharmacoEconomics, Springer, vol. 30(11), pages 981-989, November.
  74. Tracy Lieu & G. Ray & Ismael Ortega-Sanchez & Ken Kleinman & Donna Rusinak, 2009. "Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster," PharmacoEconomics, Springer, vol. 27(12), pages 1005-1016, December.
  75. Arthur E. Attema & Marieke Krol & Job Exel & Werner B. F. Brouwer, 2018. "New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 277-291, March.
  76. Frank R. Lichtenberg, 2017. "How Cost-Effective Are New Cancer Drugs in the U.S.?," CESifo Working Paper Series 6683, CESifo Group Munich.
  77. Miraldo, M & Galizzi, M & Stavropoulou, C, 2013. "In sickness but not in wealth: Field evidence on patients’ risk preferences in the financial and health domain," Working Papers 31053, Imperial College, London, Imperial College Business School.
  78. Taehwan Park & Hyemin Kim & Seunghyun Song & Scott K. Griggs, 2022. "Economic Evaluation of Pharmacist-Led Digital Health Interventions: A Systematic Review," IJERPH, MDPI, vol. 19(19), pages 1-16, September.
  79. Lars Hein & Pete Roberts & Lucia Gonzalez, 2016. "Valuing a Statistical Life Year in Relation to Clean Air," Journal of Environmental Assessment Policy and Management (JEAPM), World Scientific Publishing Co. Pte. Ltd., vol. 18(04), pages 1-24, December.
  80. Stephanie Earnshaw & Cheryl McDade & Libby Black & Christopher Bell & Michael Kattan, 2010. "Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient Populations," PharmacoEconomics, Springer, vol. 28(6), pages 489-505, June.
  81. repec:imp:wpaper:12579 is not listed on IDEAS
  82. Marion S. Rauner & Walter J. Gutjahr & Kurt Heidenberger & Joachim Wagner & Joseph Pasia, 2010. "Dynamic Policy Modeling for Chronic Diseases: Metaheuristic-Based Identification of Pareto-Optimal Screening Strategies," Operations Research, INFORMS, vol. 58(5), pages 1269-1286, October.
  83. Weidema, Bo Pedersen, 2009. "Using the budget constraint to monetarise impact assessment results," Ecological Economics, Elsevier, vol. 68(6), pages 1591-1598, April.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.